solute carrier family 39 member 9Genealiases: ZIP-9 · ZIP9
Q-omics provides the consensus-scored SLC39A9 profile across patient tissues and cancer cell-line models. SLC39A9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC39A9 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, SLC39A9 RNA expression shows 20,138 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where SLC39A9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC39A9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC39A9 survival associations across molecular data types. SLC39A9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC39A9 RNA expression–survival associations across cancer types. High SLC39A9 expression shows unfavorable associations in UVM, BLCA, ACC, LUAD and HNSC, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC39A9 RNA expression.
This table summarizes SLC39A9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC39A9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC39A9 shows lower tumor expression in THCA and KIRC and higher tumor expression in BLCA, HNSC, STAD and LIHC. The BLCA box plot shows higher SLC39A9 RNA expression in tumor versus normal tissue (log2 FC = +1.009, t-test p < 0.001).
This table shows molecular features associated with SLC39A9 in patient tissues and cancer cell lines. In patient samples, SLC39A9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC39A9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
